Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 160

2.

Genomic abnormalities in monoclonal gammopathy of undetermined significance.

Fonseca R, Bailey RJ, Ahmann GJ, Rajkumar SV, Hoyer JD, Lust JA, Kyle RA, Gertz MA, Greipp PR, Dewald GW.

Blood. 2002 Aug 15;100(4):1417-24.

3.

Detection of t(4;14)(p16.3;q32) chromosomal translocation in multiple myeloma by double-color fluorescent in situ hybridization.

Finelli P, Fabris S, Zagano S, Baldini L, Intini D, Nobili L, Lombardi L, Maiolo AT, Neri A.

Blood. 1999 Jul 15;94(2):724-32.

4.

The Ig heavy chain gene is frequently involved in chromosomal translocations in multiple myeloma and plasma cell leukemia as detected by in situ hybridization.

Nishida K, Tamura A, Nakazawa N, Ueda Y, Abe T, Matsuda F, Kashima K, Taniwaki M.

Blood. 1997 Jul 15;90(2):526-34.

5.

Cytogenetics of multiple myeloma: interpretation of fluorescence in situ hybridization results.

Harrison CJ, Mazzullo H, Cheung KL, Gerrard G, Jalali GR, Mehta A, Osier DG, Orchard KH.

Br J Haematol. 2003 Mar;120(6):944-52.

PMID:
12648063
6.

Molecular cytogenetic aberrations in patients with multiple myeloma studied by interphase fluorescence in situ hybridization.

Chen L, Li J, Xu W, Qiu H, Zhu Y, Zhang Y, Duan L, Qian S, Lu H.

Exp Oncol. 2007 Jun;29(2):116-20.

PMID:
17704743
7.

Characterization of oncogene dysregulation in multiple myeloma by combined FISH and DNA microarray analyses.

Fabris S, Agnelli L, Mattioli M, Baldini L, Ronchetti D, Morabito F, Verdelli D, Nobili L, Intini D, Callea V, Stelitano C, Lombardi L, Neri A.

Genes Chromosomes Cancer. 2005 Feb;42(2):117-27.

PMID:
15543617
8.

High incidence of cryptic translocations involving the Ig heavy chain gene in multiple myeloma, as shown by fluorescence in situ hybridization.

Avet-Loiseau H, Brigaudeau C, Morineau N, Talmant P, Laï JL, Daviet A, Li JY, Praloran V, Rapp MJ, Harousseau JL, Facon T, Bataille R.

Genes Chromosomes Cancer. 1999 Jan;24(1):9-15.

PMID:
9892103
9.

Evolutionary sequence of cytogenetic aberrations during the oncogenesis of plasma cell disorders. Direct evidence at single cell level.

Nagy Z, Kajtár B, Jáksó P, Dávid M, Kosztolányi S, Hermesz J, Kereskai L, Pajor L, Alpár D.

Leuk Res. 2011 Aug;35(8):1114-6. doi: 10.1016/j.leukres.2011.02.010. Epub 2011 Mar 5.

PMID:
21377730
11.

Translocations involving the immunoglobulin heavy-chain locus are possible early genetic events in patients with primary systemic amyloidosis.

Hayman SR, Bailey RJ, Jalal SM, Ahmann GJ, Dispenzieri A, Gertz MA, Greipp PR, Kyle RA, Lacy MQ, Rajkumar SV, Witzig TE, Lust JA, Fonseca R.

Blood. 2001 Oct 1;98(7):2266-8.

12.

Multicolor interphase cytogenetics for the study of plasma cell dyscrasias.

Sáez B, Martín-Subero JI, Odero MD, Prosper F, Cigudosa JC, Schoch R, Calasanz MJ, Siebert R.

Oncol Rep. 2007 Nov;18(5):1099-106.

PMID:
17914559
13.

A novel chromosomal translocation t(4; 14)(p16.3; q32) in multiple myeloma involves the fibroblast growth-factor receptor 3 gene.

Richelda R, Ronchetti D, Baldini L, Cro L, Viggiano L, Marzella R, Rocchi M, Otsuki T, Lombardi L, Maiolo AT, Neri A.

Blood. 1997 Nov 15;90(10):4062-70.

14.

Timing of acquisition of deletion 13 in plasma cell dyscrasias is dependent on genetic context.

Chiecchio L, Dagrada GP, Ibrahim AH, Dachs Cabanas E, Protheroe RK, Stockley DM, Orchard KH, Cross NC, Harrison CJ, Ross FM; UK Myeloma Forum.

Haematologica. 2009 Dec;94(12):1708-13. doi: 10.3324/haematol.2009.011064.

15.

Immunohistochemical analysis identifies two cyclin D1+ subsets of plasma cell myeloma, each associated with favorable survival.

Cook JR, Hsi ED, Worley S, Tubbs RR, Hussein M.

Am J Clin Pathol. 2006 Apr;125(4):615-24.

PMID:
16627271
16.

Detection of 14q32 rearrangements in multiple myeloma, using simultaneous FISH analysis combined with immunofluorescence.

Abaza HM, Youssef SR, Saad AA, Kamal GM, Hegazy MG, Ibrahim RI, Annaka LM.

Hematol Oncol Stem Cell Ther. 2015 Jun;8(2):56-63. doi: 10.1016/j.hemonc.2015.04.002. Epub 2015 Apr 22.

17.

High incidence of translocations t(11;14)(q13;q32) and t(4;14)(p16;q32) in patients with plasma cell malignancies.

Avet-Loiseau H, Li JY, Facon T, Brigaudeau C, Morineau N, Maloisel F, Rapp MJ, Talmant P, Trimoreau F, Jaccard A, Harousseau JL, Bataille R.

Cancer Res. 1998 Dec 15;58(24):5640-5.

18.

The Mi15 monoclonal antibody (anti-syndecan-1) is a reliable marker for quantifying plasma cells in paraffin-embedded bone marrow biopsy specimens.

Costes V, Magen V, Legouffe E, Durand L, Baldet P, Rossi JF, Klein B, Brochier J.

Hum Pathol. 1999 Dec;30(12):1405-11.

PMID:
10667416
19.

Detection of chromosome 13q deletions and IgH translocations in patients with multiple myeloma by FISH: comparison with karyotype analysis.

Chang H, Li D, Zhuang L, Nie E, Bouman D, Stewart AK, Chun K.

Leuk Lymphoma. 2004 May;45(5):965-9.

PMID:
15291356
20.

Myeloma and the t(11;14)(q13;q32); evidence for a biologically defined unique subset of patients.

Fonseca R, Blood EA, Oken MM, Kyle RA, Dewald GW, Bailey RJ, Van Wier SA, Henderson KJ, Hoyer JD, Harrington D, Kay NE, Van Ness B, Greipp PR.

Blood. 2002 May 15;99(10):3735-41.

Supplemental Content

Support Center